started · updated
Moderna shares hit four-year high on cancer vaccine news
Moderna shares reached a four-year high, climbing approximately 14% to $225 following reports of a major initiative to accelerate cancer vaccine development. The surge is driven by news of a planned public-private partnership involving the National Institutes of Health (NIH), research institutions, and pharmaceutical companies, modeled after the collaborative efforts used during the COVID-19 pandemic. The program is expected to launch in December.
In addition to the vaccine news, Moderna is rejoining the Nasdaq-100 index, replacing Warner Bros. Discovery. This move is expected to drive further institutional demand. While Bank of America raised its price target for Moderna to $200 from $170, it maintained a ‘Neutral’ rating, reflecting a cautious outlook despite the stock's significant momentum.
The progress in mRNA technology for oncology has also positively impacted other biotech firms, including Pfizer, BioNTech, and Merck.
Entities
Bank of America · Cantor Fitzgerald · Merck · Micron · Moderna · Nasdaq-100 · National Institutes of Health · Nvidia · SK Hynix · TSMC
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 4 SOURCES] A planned public-private partnership aims to accelerate cancer vaccine development. biznisinfo.mk · www.it-boltwise.de · www.ad-hoc-news.de · newsable.asianetnews.com
- [● 2 SOURCES] Bank of America raised its price target for Moderna to $200 from $170 while maintaining a Neutral rating. www.ad-hoc-news.de · newsable.asianetnews.com
- [● 2 SOURCES] Moderna is rejoining the Nasdaq-100 index, replacing Warner Bros. Discovery. newsable.asianetnews.com · www.sharedeals.de
- [● 2 SOURCES] Moderna shares rose approximately 14% to reach a 52-week high of $225. biznisinfo.mk · newsable.asianetnews.com
- [● 4 SOURCES] The cancer vaccine program is expected to launch in December. biznisinfo.mk · www.it-boltwise.de · www.ad-hoc-news.de · newsable.asianetnews.com